EGFR and non-small cell lung carcinoma: In addition, the dual HDAC and 3-hydroxy-3-methylgutaryl coenzyme A reductase inhibitor, JMF3086, which regulate the post-translational regulation of E-cadherin, can restore the sensitivity to first and third-generation EGFR-TKI in NSCLC [130].